AMGEN INC Stock: price and insider trades · United States · SEC (Form 4)

About AMGEN INC

Amgen Inc. is a major U.S. biopharmaceutical company listed on the NASDAQ under ticker AMGN, with headquarters in Thousand Oaks, California, United States. Founded in 1980, Amgen is widely regarded as one of the pioneers of modern biotechnology and played an important role in helping establish the biotech industry from its earliest years. Today, the company is one of the leading independent biotechnology firms globally, with a business model focused on discovering, developing, manufacturing, and commercializing innovative medicines for serious and chronic diseases. ([amgen.com](https://www.amgen.com/about?utm_source=openai)) Amgen’s core business is organized around four therapeutic areas: general medicine, rare diseases, inflammation, and oncology. Its portfolio includes several well-established brands that matter to institutional investors, including Repatha for cholesterol lowering and cardiovascular risk reduction, Enbrel in inflammatory disease, Prolia and Xgeva in bone health, Otezla in psoriasis and inflammatory conditions, and Tezspire in severe asthma. Following the Horizon Therapeutics acquisition, Amgen strengthened its exposure to rare disease and specialized immunology assets such as Tepezza, Krystexxa, and Uplizna. ([amgen.com](https://www.amgen.com/products?utm_source=openai)) From a competitive standpoint, Amgen combines scale, a diversified commercial base, and a sizeable portfolio of mature products with an active pipeline. Management emphasizes the company’s use of biology, human genetic data, and technology to accelerate innovation and improve manufacturing efficiency. Geographically, Amgen has a strong U.S. base but also generates sales across multiple international regions, giving it broad global reach while remaining firmly anchored in the United States market. ([amgen.com](https://www.amgen.com/about?utm_source=openai)) Recent developments are strategically important. In 2025 and 2026, Amgen reported positive phase 3 data for Repatha in primary cardiovascular prevention, encouraging clinical updates for Tezspire and Uplizna, and a new $300 million investment in its U.S. manufacturing network. The company also announced a $900 million expansion in Ohio and a more than $600 million science-and-innovation center at its Thousand Oaks headquarters. These actions reinforce Amgen’s current strategy: expand its industrial footprint, support supply reliability, and continue advancing high-value therapies across key disease areas. ([amgen.com](https://www.amgen.com/newsroom/press-releases/2025/10/landmark-phase-3-trial-vesaliuscv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12000-patients?utm_source=openai))